|By Business Wire||
|June 27, 2014 12:00 PM EDT||
Eckert & Ziegler Radiopharma GmbH has received a recommendation from the European Medicines Agency for approval of its pharmaceutical 68Ge/68Ga generators. This achievement marks the conclusion of a comprehensive decentralized evaluation procedure and the first time a gallium generator has been approved for the clinical development of highly specific diagnostic agents. Approval for sale in the respective countries is expected within the next one to two months.
Gallium generators provide an inexpensive alternative for radiolabeling diagnostic probes using positron emission tomography (PET), an imaging process that can be used to determine whether tissue is diseased. The process is mainly used in cancer treatment. Until now, fluorine-18 or carbon-11 PET radioisotopes have usually been used to radiolabel diagnostic probes; these radioisotopes are produced using cyclotrons that are capitally intensive, large-scale dedicated installations requiring millions in investment. In contrast, the gallium generator is approximately the size of a thermos and can be sourced for far less money, lowering costs and increasing flexibility at nuclear medicine clinics.
Once it has received approval, Eckert & Ziegler will also submit its documents to the U.S. Food and Drug Administration (FDA), establishing a Drug Master File with the agency. This will allow parties interested in developing new drugs to refer to the dossier and use the generator in clinical tests of medications and in other settings.
Dr. André Heß, Member of the Executive Board of Eckert & Ziegler AG and Head of the Radiopharma segment, says: “We are proud to have gotten the ball rolling on the world’s first approval of a pharmaceutical 68Ge/68Ga generator. We would also like to encourage academic research and development departments in the global pharmaceutical industry to introduce more substances that can be radiolabeled with Ga-68 into clinical development. ‘Theranostic’ approaches that combine diagnosis using Ga-68 PET with treatment using Yttrium-90, coupled using the same carrier molecule, are also very promising.”
Eckert & Ziegler operates a network of cyclotrons in central and eastern Europe and manufactures pharmaceutical Yttrium-90 (EU-approved product: Yttriga). The company has developed a customized technology platform for the local production of radiopharmaceuticals (designed especially for Ga-68 and Y-90-based pharmaceuticals) that allows clinical users to perform all processes, from synthesis and quality control to patient dose preparation.
Eckert & Ziegler (ISIN DE0005659700), with approximately 700 employees, is one the world’s largest providers of isotope technology for radiation therapy and nuclear medicine.
Jan. 16, 2017 11:45 PM EST Reads: 4,177
Jan. 16, 2017 11:30 PM EST Reads: 3,507
Jan. 16, 2017 09:00 PM EST Reads: 7,436
Jan. 16, 2017 08:45 PM EST Reads: 4,576
Jan. 16, 2017 08:00 PM EST Reads: 619
Jan. 16, 2017 06:45 PM EST Reads: 3,487
Jan. 16, 2017 06:00 PM EST Reads: 370
Jan. 16, 2017 05:00 PM EST Reads: 4,013
Jan. 16, 2017 03:30 PM EST Reads: 4,823
Jan. 16, 2017 03:15 PM EST Reads: 355
Jan. 16, 2017 02:30 PM EST Reads: 1,549
Jan. 16, 2017 02:15 PM EST Reads: 5,267
Jan. 16, 2017 01:45 PM EST Reads: 3,594
Jan. 16, 2017 01:30 PM EST Reads: 3,309
Updating DevOps to the latest production data slows down your development cycle. Probably it is due to slow, inefficient conventional storage and associated copy data management practices. In his session at @DevOpsSummit at 20th Cloud Expo, Dhiraj Sehgal, in Product and Solution at Tintri, will talk about DevOps and cloud-focused storage to update hundreds of child VMs (different flavors) with updates from a master VM in minutes, saving hours or even days in each development cycle. He will also...
Jan. 16, 2017 01:00 PM EST Reads: 1,031